Therapeutic potential for CD39 in renal transplantation: There is hope

American Journal of Transplantation

Volumn 10, Issue 12, 2010, Pages 2567-2568

  Laubach, V E ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; CD39 ANTIGEN;

DELAYED GRAFT FUNCTION; EDITORIAL; GRAFT SURVIVAL; KIDNEY ISCHEMIA; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; REPERFUSION INJURY;

ADENOSINE; ANTIGENS, CD; APYRASE; DELAYED GRAFT FUNCTION; HUMANS; KIDNEY TRANSPLANTATION; RECEPTOR, ADENOSINE A2A; REPERFUSION INJURY; TRANSPLANTATION IMMUNOLOGY;

EID: 78649876274     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03300.x     Document Type: Editorial

References (5)

1. Collins AJ, Foley RN, Herzog C, et al,. Excerpts from the US renal data system 2009 Annual Data Report. Am J Kidney Dis 2010; 55 (1 Suppl 1): S1-420, A426- 427.
2. Yarlagadda SG, Coca SG, Formica RN Jr, Poggio ED, Parikh CR,. Association between delayed graft function and allograft and patient survival: A systematic review and meta-analysis. Nephrol Dial Transplant 2009; 24: 1039-1047.
3. Crikis S, Lu B, Murray-Segal LM, et al,. Transgenic overexpression of CD39 protects against renal ischemia-reperfusion and transplant vascular injury. Am J Transplant 2010. In press.
4. Robson SC, Wu Y, Sun X, Knosalla C, Dwyer K, Enjyoji K,. Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation. Semin Thromb Hemost 2005; 31: 217-233.
5. Blackburn MR, Vance CO, Morschl E, Wilson CN,. Adenosine receptors and inflammation. Handb Exp Pharmacol 2009; 193: 215-269.